NASHVILLE, Tenn. and
TOKYO, Aug.
4, 2020 /PRNewswire/ -- Cryoport,
Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in life
sciences supply chain solutions, and MEDIPAL HOLDINGS
CORPORATION (7459:JP), ("MEDIPAL") Japan's leading pharma wholesaler and
distributor today announced a multi-year strategic business
alliance agreement to create an integrated regenerative medicine
supply chain solution in Japan.
Cryoport and MEDIPAL will partner to provide integrated,
end-to-end distribution solutions for specialty cell and gene
therapies that demand stringent temperature control, track and
trace systems and global distribution. To meet demand from the
increasing number of cell and gene therapies currently in
development and expected to launch in coming years, this alliance
will combine both companies' strengths to realize reliable and
seamless distribution services for biopharmaceutical companies in
Japan and the Asia-Pacific ("APAC") region / worldwide.
Cryoport supports over 465 clinical trials, globally, and
multiple cell and gene therapies in commercial distribution. Its
suite of unique temperature-controlled solutions for the life
sciences industry enables users to monitor their shipments and
track the conditions, location, and courier handling of their
biological commodities in transit around the clock. And should a
problem occur that warrants intervention, Cryoport can deploy
intervention capability to mitigate the situation.
MEDIPAL provides industry-leading efficient, reliable, and
timely distribution solutions for specialty products in the
healthcare industry across a broad range of temperatures, from
-196℃ to 37℃ (-320℉ to 99℉), with strict temperature
control and traceability. With its high-quality logistics,
including the original SDDU (Specialty Drug Distribution Unit: a
long-life shipping unit using liquid nitrogen in liquid phase for
ultra-low temperature logistics), MEDIPAL has positioned itself as
a unique leader in cell and gene therapy product logistics in
Japan. The goal of the partnership
is to provide fully integrated solutions that reduce risk and
improve certainty for the companies' Japan and global clients and build business
revenue for both MEDIPAL and Cryoport.
Shuichi Watanabe, Representative
Director, President and CEO said, "This alliance with Cryoport will
enable our two companies to seamlessly provide an integrated,
high-quality logistics service in the Japanese market, as well as
overseas, complementing each other's strengths. We also believe
that this alliance will accelerate our progress to satisfy unmet
medical needs, both domestically and internationally, and it will
help patients awaiting new treatment options, as well as the
treating physicians."
Jerrell Shelton, CEO of Cryoport,
added, "Cryoport's Chain of Compliance® complete suite of
technologies and informatics are trusted by biopharmaceutical
companies worldwide. We use SmartPak™ Condition Monitoring System
and Cryoportal™ technologies to monitor the conditions of cell and
gene therapies in real-time from the time of packing through
transit to unpacking thereby significantly mitigating potential
risks. We look forward to this alliance with MEDIPAL and to growing
together in the cell and gene therapy space in Japan and globally."
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX) is
redefining logistics for the life sciences industry by providing a
platform of temperature-controlled solutions, serving the
Biopharma, Reproductive Medicine, and Animal Health markets. Our
mission is to support life and health on earth by providing
reliable and comprehensive solutions for the life sciences industry
through our advanced technologies, Global Supply Chain Network and
dedicated scientists, technicians and supporting team of
professionals. Through its purpose-built, proprietary Cryoport
Express® Shippers; Cryoportal® information technology; validated
Global Logistics Centers; smart and sustainable
temperature-controlled logistics; and biostorage/biobanking
services, Cryoport serves clients in life sciences research,
clinical trials, and product commercialization. We support
life-saving advanced cell and gene therapies and deliver vaccines,
protein producing materials, and IVF materials in over 100
countries around the world. For more information, visit
www.cryoport.com or follow @cryoport on Twitter at
www.twitter.com/cryoport for live updates.
About MEDIPAL
HOLDINGS CORPORATION
|
Name:
|
MEDIPAL HOLDINGS
CORPORATION
|
Established:
|
May 1923
|
Business:
|
As a holding company,
MEDIPAL controls, administers and supports the operating activities
of companies in which it holds shares in the Prescription
Pharmaceutical Wholesale Business; the Cosmetics, Daily Necessities
and OTC Pharmaceutical Wholesale Business; and the Animal Health
Products and Food Processing Raw Materials Wholesale Business, and
conducts business development for the MEDIPAL Group.
|
Head
office:
|
Chuo-ku, Tokyo,
Japan
|
Website:
|
https://medipal.co.jp/english
|
Representative:
|
Shuichi Watanabe,
Representative Director, President and CEO
|
Forward Looking Statements
Statements in this news
release which are not purely historical, including statements
regarding Cryoport, Inc.'s intentions, hopes, beliefs,
expectations, representations, projections, plans or predictions of
the future are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. It is important
to note that the Company's actual results could differ materially
from those in any such forward-looking statements. Factors that
could cause actual results to differ materially include, but are
not limited to, risks and uncertainties associated with the effect
of changing economic conditions, trends in the products markets,
variations in the Company's cash flow, market acceptance risks, and
technical development risks. The Company's business could be
affected by a number of other factors, including the risk factors
listed from time to time in the Company's SEC reports including,
but not limited to, the Company's 10-K for the year ended
December 31, 2019 filed with the SEC.
The Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release.
Cryoport, Inc. disclaims any obligation, and does not undertake to
update or revise any forward-looking statements in this press
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/medipal-holdings-partners-with-cryoport-to-bring-temperature-controlled-supply-chain-solutions-to-the-japanese-market-301104607.html
SOURCE Cryoport, Inc.